Recently, the Shanghai Municipal Government released the "Several Opinions on Supporting Innovation and Development Across the Entire Biopharmaceutical Industry Chain," aiming to comprehensively boost innovation and growth in the biopharmaceutical sector through a series of policy measures. The initiative covers eight key areas—research and development, clinical trials, regulatory review and approval, application promotion, industrialization implementation, investment and financing, data resources, and internationalization—and includes 37 specific actions.

Several Opinions of the General Office of the Shanghai Municipal People's Government on Supporting Innovation and Development Across the Entire Biopharmaceutical Industry Chain

Shanghai Municipal Government Office Regulation No. 9 of 2024

To the People's Governments of all districts, and to all commissions, offices, and bureaus of the Municipal Government:

Developing the biopharmaceutical industry is a key strategy for accelerating the creation of new, high-quality productivity. To further establish a global strategic hub for major biopharmaceutical industries in the new era—and to support the city’s high-quality economic and social development—we hereby present the following measures to foster innovative, full-chain development across the biopharmaceutical sector:

1. Significantly enhance the capacity for innovation and knowledge generation

(1) Accelerate innovation in fundamental theories and breakthroughs in cutting-edge technologies. Leverage the role of national strategic science and technology platforms as innovation hubs, focusing on transformative and emerging fields such as cell and gene therapy, mRNA, synthetic biology, and regenerative medicine—areas that represent both foundational frontiers and new growth opportunities. Conduct research into novel targets, mechanisms, and structures, while simultaneously positioning ourselves to tackle pioneering technologies and develop next-generation therapeutics. Strengthen the development of high-end medical devices, advanced pharmaceutical equipment and materials, and modern traditional Chinese medicine. (Responsible units: Municipal Science and Technology Commission, Municipal Development and Reform Commission)

(II) Supporting AI technologies to empower drug discovery and development. Leveraging cutting-edge technologies such as generative AI and deep learning, the initiative will focus on key areas including the discovery and validation of novel drug targets, drug discovery and design, innovative drug screening, and medication safety analysis. It aims to accelerate breakthroughs in models, algorithms, specialized software, and the development of shared platforms, while also demonstrating intelligent application scenarios across these domains. (Responsible Units: Municipal Science and Technology Commission, Municipal Commission of Economy and Information Technology, Municipal Development and Reform Commission)

(III) Supporting programs for top-tier scientists and outstanding young talents. Support global top-tier scientists and master-level experts who hold core intellectual property (IP) rights to pursue groundbreaking theoretical and technological breakthroughs in Shanghai, with support provided on a case-by-case basis. Additionally, prioritize and provide enhanced support for outstanding young talents in areas such as the foundational research pilot zones and various talent programs. (Responsible units: Shanghai Municipal Talent Bureau, Shanghai Municipal Science and Technology Commission, Shanghai Municipal Commission of Economy and Informatization)

(4) Accelerate the translation of scientific research findings into preclinical studies. Establish a subsidized support mechanism that uses metrics such as the number of approved drug clinical trial applications and the volume of locally translated research outcomes as key performance indicators. This initiative will encourage Contract Research Organizations (CROs) to provide preclinical drug research services to university-based research institutions, offering annual interest subsidies of up to RMB 10 million per project as stipulated. Additionally, enterprises are encouraged to lead the establishment of multi-stakeholder, full-chain innovation and technology transfer consortia. (Responsible Units: Municipal Development and Reform Commission, Municipal Science and Technology Commission, Municipal Finance Bureau)

(5) Continue to significantly increase support for innovative drug research and development. For Class 1 new drugs that are developed by applicants registered in our city, undergo domestic Phase I, Phase II, or Phase III clinical trials, and successfully achieve commercialization, we will provide preferential funding of up to 40% of the R&D investment—capped at RMB 10 million for Phase I, RMB 20 million for Phase II, and RMB 30 million for Phase III—as per established regulations. Additionally, for Class 1 cell and gene therapy drugs that only require early-stage or confirmatory clinical trials, we will offer preferential support of up to RMB 15 million for early-phase trials and up to RMB 30 million for confirmatory trials, respectively, subject to regulatory approval. The total annual support for each entity will not exceed RMB 100 million. (Responsible Units: Municipal Science and Technology Commission, Municipal Development and Reform Commission, Municipal Drug Administration, Municipal Finance Bureau)

(6) Continue to significantly increase support for the development of innovative medical devices. Products entering the national and municipal special review process for innovative medical devices will receive support of up to 3 million yuan, as per regulations. Additionally, for these products that successfully obtain their first registration certificate and commence production, an extra subsidy of up to 40% of the R&D investment—capped at 8 million yuan—will be provided, also according to established rules. Each organization can receive cumulative annual support totaling no more than 30 million yuan. (Responsible units: Municipal Science and Technology Commission, Municipal Development and Reform Commission, Municipal Drug Administration, Municipal Finance Bureau)

II. Enhancing the Role of Clinical Resources in Driving Industry Development

(7) Support the development of research-oriented hospitals. Promote the construction of the Shanghai Clinical Research Center. Encourage well-equipped, high-level hospitals to transition into research-oriented institutions whose primary function is clinical innovation and research activities. Additionally, these hospitals are encouraged to establish research-focused beds at 10% of their approved bed capacity, while also developing fully functional, centrally managed, and collaboratively shared research wards. Private capital is also invited to invest in the development of research-oriented hospitals. (Responsible Units: Shanghai Municipal Health Commission, Shenkang Hospital Development Center, Shanghai Municipal Development and Reform Commission, Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance Bureau)

(8) Optimize and improve the mechanism for translating clinical research into practical applications. Leveraging the role of the Shanghai Clinical Innovation and Translation Institute, hospitals will be allowed to contribute intangible assets—valued at market price—as equity investments, with the resulting equity shares held on their behalf by the Institute, enabling them to capture corresponding equity returns. The institute will also implement the third phase of the "Three-Year Action Plan to Enhance Clinical Skills and Innovation in Municipal Hospitals," supporting high-level hospitals in advancing medical innovation and accelerating the translation of research findings into practical applications. Additionally, eligible hospital researchers will be encouraged to initiate cutting-edge clinical studies. (Responsible entities: Shenkang Hospital Development Center, Shanghai Municipal Health Commission, Shanghai Municipal Science and Technology Commission, Shanghai Municipal State-owned Assets Supervision and Administration Commission, and Shanghai Municipal Finance Bureau)

(9) Shorten the clinical trial initiation time. Coordinate and integrate city-wide health and medical data to build a comprehensive cohort database, while establishing a high-quality, state-of-the-art biobank along with robust management standards. Develop preclinical cohorts for major diseases such as cancer, cardiovascular and cerebrovascular conditions, metabolic disorders, and mental and neurological illnesses, ensuring rapid enrollment of participants. Strive to reduce the total time required for clinical trial initiation within healthcare institutions to no more than 25 weeks. (Responsible entities: Shanghai Municipal Health Commission, Shenkang Hospital Development Center, Shanghai Municipal Data Administration, Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance Bureau)

(10) Enhance the efficiency of medical ethics reviews. Establish a streamlined "one set of documents, one submission" mechanism for ethical review, concurrently conducting pre-review by the project management department, formal ethical review, and contract pre-approval procedures. This approach will enhance the efficiency and frequency of ethical review meetings. The lead institution (primary reviewing body) should complete the review and issue its opinion within 15 working days of receiving the application, while participating institutions opting for the simplified review process must deliver their feedback within 5 working days. Together, these measures aim to reduce the overall ethical review process to no more than 3 weeks. Additionally, multi-center clinical research studies are encouraged to have participating institutions proactively recognize the ethical review outcomes from the lead institution, further promoting the mutual acceptance of medical ethics review results across the city. (Responsible Units: Municipal Health Commission, Municipal Drug Administration, and Shenkang Hospital Development Center)

(11) Establish an incentive mechanism for clinical trial teams in medical institutions. Promote healthcare institutions to refine the salary distribution mechanisms for clinical trial teams, and encourage the use of clinical research efforts and their outcomes as key references in title evaluations, job competitions, and performance assessments. Additionally, qualified clinical trial leadership projects will be recognized as equivalent to municipal-level scientific research initiatives. (Responsible units: Municipal Health Commission, Municipal Human Resources and Social Security Bureau, Municipal Science and Technology Commission, and Shenkang Hospital Development Center)

(12) Align with international standards to conduct high-level clinical trial projects. Eligible Contract Research Organizations (CROs) will be supported in aligning with international standards to enhance their clinical trial service capabilities. Each selected project will receive up to RMB 1 million in funding, based on established criteria. Additionally, high-level innovative product clinical trials conducted overseas will be eligible for prioritized support of up to RMB 20 million per project, again subject to rigorous evaluation. Each organization can receive a total annual support of no more than RMB 100 million. (Responsible Units: Municipal Science and Technology Commission, Municipal Drug Administration, Municipal Finance Bureau, and Shenkang Hospital Development Center)

(13) Enhance the clinical trial liability risk compensation mechanism. Insurance institutions are encouraged to develop domestic clinical trial and product liability insurance, as well as overseas clinical trial and high-end medical equipment liability insurance. Eligible insured companies will receive support equivalent to 50% of their actual premium payments, capped at RMB 500,000 for the former and RMB 1 million for the latter, as per regulations. (Responsible entities: Shanghai Municipal Science and Technology Commission, Shanghai Bureau of Financial Regulation, Shanghai Municipal Administration of Drug Supervision, and Shanghai Municipal Finance Bureau)

3. Further Accelerate Review and Approval Processes

(14) Seek support from the national registration review process. Promote the implementation of national reform pilot programs by reducing the review timeline for supplementary drug applications to 60 working days and shortening the review and approval period for clinical trial applications to 30 working days. Support the Shanghai-based Yangtze River Delta Regional Center of the National Medical Products Administration (NMPA) in enhancing its capabilities for reviewing and inspecting pharmaceuticals and medical devices, enabling it to play a more significant role in the evaluation, review, and inspection of products in key areas. Additionally, accelerate research into detailed guidelines for continuous manufacturing production processes. (Responsible Units: Municipal Drug Regulatory Bureau, Municipal Science and Technology Commission)

(15) Strengthen proactive guidance services for registration reviews. Focus on key R&D products and projects, and implement a dedicated task force mechanism with specialized personnel from the drug regulatory authority providing guidance. This includes proactively engaging in critical stages such as clinical research, manufacturing licensing, marketing authorization, and inspection/testing. Additionally, measures like preliminary checks, end-to-end online processing, immediate review upon arrival, and intelligent evaluation will be put in place. Priority will be given to registration sampling and GMP compliance inspections for drugs under intensive R&D. For Class III medical devices in advanced development, services such as pre-review of submission materials and prioritized scheduling of registration testing will also be offered. (Responsible Units: Municipal Drug Administration Bureau, Municipal Science and Technology Commission, Municipal Health Commission)

(Sixteen) Accelerate the review and approval process for Class II medical devices. For Class II medical devices with clear clinical value and high innovation, applicants are encouraged to submit requests for the special review procedure, ensuring priority scheduling of registration testing, technical evaluation, and regulatory system inspections. Medical device products that are either the first of their kind nationwide or meet criteria for priority approval will be handled accordingly. The average review timeline for Class II medical devices has been streamlined to within 40 working days. (Responsible Unit: Municipal Drug Administration)

(17) Enhance the capacity of pharmaceutical and medical device registration testing services. Support pharmaceutical and medical device inspection and testing institutions in strengthening the development of specialized technical service platforms related to biological products, implantable medical devices, large-scale medical equipment, and medical software—providing enterprises with services such as product safety assessments, quality control, registration and filing, risk evaluations, inspection and testing, and technical training. (Responsible units: Municipal Drug Administration Bureau, Municipal Science and Technology Commission, Municipal Development and Reform Commission)

4. Accelerate the Application and Promotion of Innovative Products

(18) Encourage the inclusion and use of innovative products in hospital settings. Continuously update the catalog of "New and Superior Drugs & Medical Devices," establish a "green channel" for innovative products to be listed on the platform, and recommend their inclusion in national medical insurance drug lists or coverage under programs like "Hu Huibao." Within one month of the release of updates to national medical insurance drugs and "New and Superior Drug/Medical Device" products, healthcare institutions in our city will procure and deploy these innovative solutions—adhering to the principle of "providing as much as needed"—based on clinical requirements and each hospital's unique strengths. Eligible pharmacies will also be promptly integrated into the "dual-channel" system. Meanwhile, strengthen performance evaluations targeting innovation responsibilities at municipal-level hospitals, ensuring that medical facilities do not impose restrictions on the admission of innovative drugs and devices due to factors such as volume of prescriptions or drug/consumable cost ratios. (Responsible entities: Shanghai Municipal Science and Technology Commission, Shanghai Municipal Healthcare Security Bureau, Shanghai Municipal Health Commission, Shenkang Hospital Development Center, Shanghai Regulatory Bureau of Financial Services)

(19) Increase support for medical insurance coverage of innovative products. For medical treatment programs involving drugs selected through national healthcare negotiations and innovative medical devices, separate budget allocations will be implemented, with payments made independently under the DRG/DIP reform framework. Additionally, eligible high-value innovative medical devices and cutting-edge healthcare service projects will be grouped separately within the DRG/DIP system, allowing for enhanced payment rates without being constrained by the typical high-case-volume thresholds. Furthermore, "new, superior, and innovative" pharmaceuticals and medical devices that meet regulatory criteria will be promptly evaluated for inclusion in the national health insurance coverage system. (Responsible entities: Municipal Healthcare Security Bureau, Municipal Health Commission, Municipal Drug Administration, Municipal Science and Technology Commission, and Shenkang Hospital Development Center)

(20) Support the demonstration, application, and promotion of innovative products. Support healthcare institutions in collaborating with enterprises to launch demonstration projects for innovative medical devices and drugs, conducting post-market evaluations, real-world efficacy assessments, and studies on expanding clinical indications. Eligible projects will receive prioritized funding of up to 2 million yuan per project, as per established guidelines. Additionally, support will be provided for collaborative innovation initiatives involving government procurement in the biopharmaceutical sector. (Responsible entities: Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance Bureau, Shanghai Municipal Drug Administration, Shanghai Financial Regulatory Bureau, Shanghai Municipal Health Commission, Shanghai Municipal Healthcare Security Bureau, and Shenkang Hospital Development Center)

5. Strengthen services for businesses and support the commercialization and implementation of initiatives

(21) Establish a coordinated mechanism for addressing enterprise development issues. Leveraging city- and district-level task forces, the initiative focuses on 100 key enterprises, 100 major investment projects, 100 priority products, and 100 critical pipeline initiatives, establishing a coordinated system to address the "4 x 100" issue list. Additionally, it relies on the City's Strategic Advisory Committee for Industry-Medical Integration to create a robust platform for government-industry-academia-research-investment-finance-user collaboration and exchange. (Responsible entities: Municipal Science and Technology Commission, Municipal Drug Administration, Municipal Health Commission, and relevant district governments.)

(22) Vigorously cultivate blockbuster products. Provide targeted support for innovative products developed and commercialized in Shanghai that achieve breakthroughs in relevant output value and scale for the first time. Leverage the role of state-owned investment funds, strengthen policy support at both city and district levels, and encourage these products to expand their market presence. (Responsible entities: Shanghai Municipal Science and Technology Commission, Shanghai Municipal Development and Reform Commission, Shanghai Municipal State-owned Assets Supervision and Administration Commission, Shanghai Municipal Finance Bureau, and relevant district governments)

(23) Accelerate the advancement of major industrialization project construction. Support will be provided for the construction of projects such as process technology R&D, specialized technical service platforms, and industrialization bases, with priority funding granted—up to 30% of the approved incremental investment—as per regulations. Additionally, enterprises are encouraged to accelerate their transformation toward high-end, intelligent, and green operations, receiving priority support of up to 10% of the total approved project investment, subject to the same regulatory limits. Both initiatives are capped at a maximum support of RMB 100 million each. (Responsible Units: Municipal Science and Technology Commission, Municipal Economic and Information Technology Commission, Municipal Development and Reform Commission)

(24) Promote a new model for contract research, development, and manufacturing organizations. Support will be provided to Contract Manufacturing Organizations (CMOs) and manufacturing enterprises with established production expertise to undertake contract manufacturing activities. Importantly, there should be no investment or other affiliations between the commissioning and contracted parties. In accordance with regulations, the contracting party will receive financial support of up to 10% of the annual production value entrusted to them, with a maximum cap of RMB 5 million per product and an annual limit of RMB 10 million per enterprise. (Responsible Units: Municipal Science and Technology Commission, Municipal Drug Administration, Municipal Finance Bureau)

(25) Strengthen support and coordination for industrial project implementation. Establish a city- and district-level mechanism for industrial collaboration and coordination, strengthening city-level overall planning and dispatching to foster interconnected efforts among districts, promote information sharing, and enable complementary resource utilization. Launch 5 million square meters of standardized biopharmaceutical factory spaces, supporting eligible projects to implement the "industrial buildings upward" initiative. Encourage state-owned park management companies to actively expand and enhance their investment and financing activities, while easing performance metrics tied to rent and profit targets. (Responsible Units: Municipal Science and Technology Commission, Municipal Economic and Information Technology Commission, Municipal State-owned Assets Supervision and Administration Commission, and relevant district governments)

6. Strengthen Investment and Financing Support

(26) Cultivate mid- to long-term investors and patient capital. Leverage the roles of Shanghai's biomedical industry mother fund, biomedical industry equity investment fund, and biomedical innovation & translation fund to strengthen strategic, long-term investment support for promising companies and high-quality R&D pipelines. Encourage government-guided funds to "invest early, invest small, and invest in hard-tech sectors." Additionally, explore the establishment of a long-term performance evaluation system and a tolerance-for-failure mechanism for projects backed by state-owned funds. (Responsible units: Municipal State-owned Assets Supervision and Administration Commission, Municipal Development and Reform Commission, Municipal Science and Technology Commission, Municipal Finance Bureau, Municipal Party Committee Financial Office)

(27) Encourage the launch of Corporate Venture Capital (CVC). Support enterprises in establishing Corporate Venture Capital (CVC) funds individually or jointly, to strengthen innovation incubation and foster collaboration across the upstream and downstream segments of the industrial value chain. Eligible CVCs will receive support such as capital contributions from municipal state-owned assets and industry-focused mother funds, as well as expedited pathways for fund establishment. (Responsible Units: Municipal SASAC, Municipal Commission of Economy and Information Technology, Municipal Development and Reform Commission, Municipal Science and Technology Commission, Municipal Financial Office of the CPC Committee)

(28) Support enterprises in growing stronger through mergers, acquisitions, and restructuring. Establish the Shanghai Biomedical Industry M&A Fund, actively encouraging qualified biomedical companies to initiate and set up M&A funds tailored to their industry transformation and upgrading needs, thereby supporting enterprises in pursuing strategic acquisitions and investments along the upstream and downstream segments of the industry value chain. (Responsible Units: Shanghai State-owned Assets Supervision and Administration Commission, Shanghai Municipal Science and Technology Commission, Shanghai Municipal Financial Services Office of the CPC Committee, Shanghai Municipal Commission of Economy and Informatization, Shanghai Municipal Development and Reform Commission)

(29) Broaden corporate financing channels through diverse approaches. Strengthen credit support for enterprises through policy tools such as preferential interest rates on long-term loans for key industries and interest subsidies. Leverage the role of the city’s policy-based financing guarantee fund for SMEs and micro-enterprises, increasing the single-batch guarantee limit for biomedical SMEs and micro-innovative enterprises to up to RMB 20 million. Additionally, raise the guarantee ceiling for medium-sized biomedical innovative enterprises holding qualifications like High-Tech Enterprises, Specialized, Fine, and New Enterprises, or "Little Giant" Tech Companies, to up to RMB 30 million. (Responsible Units: Municipal Development and Reform Commission, Municipal Science and Technology Commission, Municipal Finance Bureau, Municipal Party Committee Financial Office, Shanghai Regulatory Bureau of Finance)

7. Unlocking the Value of Data-Driven Resources

(30) Establish a data-sharing mechanism for cohort study data. Promote the on-chain deployment of cohort study data, leveraging the city's comprehensive health data platform to provide cohort data analysis services—upon request—to healthcare institutions, research institutes, and enterprises and public organizations. Promote the sharing and collaborative use of genetic, cellular, and other data among hospitals. Promote the development of a real-world research information platform for rare diseases, and pilot the establishment of operational mechanisms for real-world studies on rare-disease therapies. (Responsible units: Municipal Health Commission, Municipal Data Bureau, Municipal Science and Technology Commission, and Shenkang Hospital Development Center)

(31) Enhance the mechanisms for collaborative utilization of healthcare and medical insurance data resources. Leveraging technologies such as blockchain, privacy computing, and data spaces, and building on the "Medical Insurance Big Data Innovation Laboratory," this initiative establishes a data collaboration mechanism among hospitals, medical insurance providers, commercial insurers, and pharmaceutical companies. It aims to enhance the application of data in key areas like innovative drug development, clinical diagnosis and treatment, and commercial health insurance product design, thereby accelerating the creation of cutting-edge health insurance offerings. (Responsible entities: Shanghai Municipal Healthcare Security Bureau, Shenkang Hospital Development Center, Shanghai Municipal Health Commission, Shanghai Municipal Data Administration, and Shanghai Financial Regulatory Bureau)

(32) Build high-quality corpora and industry-specific datasets. Focusing on areas such as basic research, new drug development, medical services, and insurance product innovation, the initiative aims to build several high-quality AI corpora and industry-specific datasets. It will also support enterprises and institutions in leveraging AI-powered data training facilities to develop large-scale healthcare models. (Responsible entities: Shanghai Municipal Commission of Economy and Informatization, Shanghai Municipal Development and Reform Commission, Shanghai Municipal Data Bureau, Shanghai Municipal Health Commission, Shanghai Municipal Healthcare Security Bureau, and Shenkang Hospital Development Center)

(33) Promote the compliant and secure flow of industry data. A biomedical special zone will be established at the Shanghai Data Exchange to promote the legal and compliant trading of pharmaceutical patents, clinical trial data, industry analysis data, and more. Leveraging the China (Shanghai) Pilot Free Trade Zone—specifically the Lingang New Area—this initiative will pilot initiatives supporting the secure, compliant, and cross-border flow of data for biomedical companies. (Responsible entities: Shanghai Municipal Data Bureau, Shanghai Municipal Committee Office of Cyberspace Affairs, and the Management Committee of the Lingang New Area.)

8. Promote the internationalization of industries

(34) Supporting foreign-invested enterprises in their investment and development in Shanghai. Supporting foreign-invested enterprises in establishing regional headquarters, R&D centers, open innovation platforms, proof-of-concept centers, and common technology platforms in Shanghai. In the Shanghai Pilot Free Trade Zone (including the Lingang New Area), qualified foreign-invested enterprises will be selected to pilot the expanded opening-up of gene diagnostics and therapeutic technology development and application. Exploring the promotion of cross-border biopharmaceutical production with phased manufacturing in Shanghai. (Responsible units: Shanghai Municipal Commission of Commerce, Shanghai Municipal Development and Reform Commission, Shanghai Municipal Science and Technology Commission, Shanghai Municipal Health Commission, Shanghai Municipal Administration for Drug Supervision, Pudong New Area Government, Lingang New Area Management Committee)

(35) Further enhance the convenience of goods entering and leaving the country. Optimize the pilot policy for importing R&D-related materials, refine the enterprise-credit-driven management model, and extend the pilot program to include reference standards used for trace-level testing. Specifically, exempt eligible trace-level testing reference standards from requiring import licenses issued by the agriculture and environmental protection authorities. Additionally, further expand the scope of items covered under the joint regulatory mechanism for special imported and exported goods, providing support for the import and export of cell therapy products and other related specialized items. (Responsible Units: Shanghai Municipal Commission of Commerce, Shanghai Municipal Science and Technology Commission, Shanghai Customs, Shanghai Municipal Administration for Drug Supervision)

(36) Strengthen support for global registration and certification of innovative products. For innovative drugs, modern traditional Chinese medicines, and high-end medical devices developed by enterprises in our city that have successfully obtained regulatory approvals from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the European Community (CE), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), or the World Health Organization, as well as drug regulatory agencies in BRICS countries and Belt and Road Initiative nations—once these products are launched for sale locally—we will provide preferential support of up to 30% of the R&D investment, with a maximum cap of 10 million yuan. Additionally, innovative companies are encouraged to collaborate with multinational corporations. For overseas rights licensing deals involving upfront payments exceeding 100 million yuan (where the two parties maintain no investment or other affiliations), we will offer preferential support to the licensor company, covering up to 50% of their third-party professional service expenses, subject to a maximum of 5 million yuan.

(37) Facilitate international academic and business exchanges in the pharmaceutical field. Deepen scientific and industrial cooperation and exchange in the biopharmaceutical sector among Shanghai, Hong Kong, and Macao. Support the organization of biopharmaceutical-related conferences, academic exchanges, regulatory coordination events, and more. For local enterprises or organizations participating in international events and trade shows, eligible projects will receive financial support equivalent to up to 50% of the project expenses—subject to verification—and capped at RMB 50,000 per project. The total annual support for each entity will not exceed RMB 500,000. (Responsible units: Shanghai Municipal Science and Technology Commission, Shanghai Municipal Administration for Drug Supervision, Shanghai Municipal Finance Bureau)

This policy supports enterprises, institutions, or privately-run non-enterprise entities registered and operating within our city, engaged in R&D, manufacturing, and professional services related to pharmaceuticals, medical devices, biotechnology, and life science research instruments. For initiatives that overlap with other similar policies in our city, support will be provided based on the principles of "favoring the better option, applying the higher standard, and avoiding duplication."各区 are encouraged to tailor complementary support measures according to their specific circumstances, while also strengthening policy coordination between the city and district levels.

These guidelines will take effect on August 1, 2024, and remain valid until July 31, 2029. From June 1 to July 31, 2024, relevant policy measures involving financial support will be implemented in accordance with these guidelines.

Office of the Shanghai Municipal People's Government

July 15, 2024